• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

    1.044 -0.016 (-1.54%)
    Streaming Delayed Price Updated: 11:44 AM EST, Jan 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 36,120
    Open 1.110
    Bid (Size) 1.040 (1,700)
    Ask (Size) 1.070 (400)
    Prev. Close 1.060
    Today's Range 1.030 - 1.120
    52wk Range 0.8601 - 8.969
    Shares Outstanding 3,541,262
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences Issues Annual Shareholder Letter
    Via ACCESS Newswire

    Performance

    YTD
    +11.0%
    +11.0%
    1 Month
    -26.5%
    -26.5%
    3 Month
    -55.2%
    -55.2%
    6 Month
    -50.1%
    -50.1%
    1 Year
    -86.8%
    -86.8%

    More News

    Read More
    News headline image
    Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences Reports Third Quarter 2025 Financial Results
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences Narrows Loss in Q2 ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
    Via ACCESS Newswire
    News headline image
    These stocks that are showing activity before the opening bell on Wednesday. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Ensysce Biosciences Reports First Quarter 2025 Financial Results
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences Bolsters Management Team with Regulatory Expert
    Via ACCESS Newswire
    News headline image
    Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
    Via ACCESS Newswire

    Frequently Asked Questions

    Is Ensysce Biosciences, Inc. - Common Stock publicly traded?
    Yes, Ensysce Biosciences, Inc. - Common Stock is publicly traded.
    What exchange does Ensysce Biosciences, Inc. - Common Stock trade on?
    Ensysce Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ensysce Biosciences, Inc. - Common Stock?
    The ticker symbol for Ensysce Biosciences, Inc. - Common Stock is ENSC on the Nasdaq Stock Market
    What is the current price of Ensysce Biosciences, Inc. - Common Stock?
    The current price of Ensysce Biosciences, Inc. - Common Stock is 1.044
    When was Ensysce Biosciences, Inc. - Common Stock last traded?
    The last trade of Ensysce Biosciences, Inc. - Common Stock was at 01/09/26 11:44 AM ET
    What is the market capitalization of Ensysce Biosciences, Inc. - Common Stock?
    The market capitalization of Ensysce Biosciences, Inc. - Common Stock is 3.70M
    How many shares of Ensysce Biosciences, Inc. - Common Stock are outstanding?
    Ensysce Biosciences, Inc. - Common Stock has 4M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.